These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20126838)

  • 21. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
    Wouter Jukema J; Collet JP; De Luca L
    Curr Med Res Opin; 2012 Feb; 28(2):203-11. PubMed ID: 22181345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thienopyridine antiplatelet agents: focus on prasugrel.
    Freeman MK
    Consult Pharm; 2010 Apr; 25(4):241-57. PubMed ID: 20511177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
    Thomas D; Giugliano RP
    Crit Pathw Cardiol; 2009 Mar; 8(1):12-9. PubMed ID: 19258833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late prasugrel benefit in STEMI patients?
    Serebruany VL
    Am J Ther; 2009; 16(6):469-70. PubMed ID: 19531932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
    Tcheng JE; Mackay SM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):83-91. PubMed ID: 22316323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
    Steiner S; Moertl D; Chen L; Coyle D; Wells GA
    Thromb Haemost; 2012 Aug; 108(2):318-27. PubMed ID: 22627948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
    Wiviott SD
    Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The TRITON versus PLATO trials: differences beyond platelet inhibition.
    Serebruany VL
    Thromb Haemost; 2010 Feb; 103(2):259-61. PubMed ID: 20024505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?
    Serebruany VL
    Fundam Clin Pharmacol; 2009 Aug; 23(4):411-7. PubMed ID: 19500152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prasugrel: a critical comparison with clopidogrel.
    Reinhart KM; White CM; Baker WL
    Pharmacotherapy; 2009 Dec; 29(12):1441-51. PubMed ID: 19947804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
    Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
    Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.
    Baker WL; White CM
    Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study.
    Silvain J; Cayla G; Hulot JS; Finzi J; Kerneis M; O'Connor SA; Bellemain-Appaix A; Barthélémy O; Beygui F; Collet JP; Montalescot G
    Eur Heart J; 2012 May; 33(10):1241-9. PubMed ID: 22067090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
    Salisbury AC; Wang K; Cohen DJ; Li Y; Jones PG; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2013 Jan; 6(1):27-34. PubMed ID: 23212457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prasugrel development - claims and achievements.
    Serebruany V; Shalito I; Kopyleva O
    Thromb Haemost; 2009 Jan; 101(1):14-22. PubMed ID: 19132184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
    Jakubowski JA; Winters KJ; Naganuma H; Wallentin L
    Cardiovasc Drug Rev; 2007; 25(4):357-74. PubMed ID: 18078435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel antiplatelet strategies in acute coronary syndromes.
    Sabatine MS
    Cleve Clin J Med; 2009 Apr; 76 Suppl 1():S8-15. PubMed ID: 19332592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.